1733TiP A phase I trial of the oncolytic virus SVV-001 in combination with nivolumab and ipilimumab in patients with poorly differentiated neuroendocrine carcinomas or well-differentiated grade 3 neuroendocrine tumors

Journal article

Peer reviewed

A. Chauhan, I. Reis, C.T. Jani, R. Modak, D. Bilbao, J.R. Merchan, G. Lopes, P. Hosein, P. Hallenbeck and H. Trinh

Annals of oncology, Vol.36, p.S1019

2025-09

Metrics

1 Record Views

Title: 1733TiP A phase I trial of the oncolytic virus SVV-001 in combination with nivolumab and ipilimumab in patients with poorly differentiated neuroendocrine carcinomas or well-differentiated grade 3 neuroendocrine tumors
Creators: A. Chauhan
I. Reis
C.T. Jani
R. Modak
D. Bilbao
J.R. Merchan
G. Lopes
P. Hosein
P. Hallenbeck
H. Trinh
Publication Details: Annals of oncology, Vol.36, p.S1019
Publisher: ELSEVIER; AMSTERDAM
Number of pages: 1
Grant note: University of Miami and Seneca Therapeutics
University of Miami and Seneca Therapeutics.
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991032859335902976